D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
CGEM holding history
Cullinan Therapeutics, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
CGEM overviewAll 13F holders of CGEMFull Q2 2026 holdings
- Shares (Q1 2026)
- 0
- Sold out in Q1 2026
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 17
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q1 2026 | 0 | $0 | 0.0% | −14,365−100.0% | Sold out | Holders |
| Q4 2025 | 14,365 | $148.7K | <0.1% | −11,254−43.9% | Reduced | Holders |
| Q3 2025 | 25,619 | $151.9K | <0.1% | +290+1.1% | Added | Holders |
| Q2 2025 | 25,329 | $190.7K | <0.1% | −6,165−19.6% | Reduced | Holders |
| Q1 2025 | 31,494 | $238.4K | <0.1% | −17,438−35.6% | Reduced | Holders |
| Q4 2024 | 48,932 | $596.0K | <0.1% | −10,308−17.4% | Reduced | Holders |
| Q3 2024 | 59,240 | $991.7K | <0.1% | −153,208−72.1% | Reduced | Holders |
| Q2 2024 | 212,448 | $3.71M | <0.1% | +150,827+244.8% | Added | Holders |
| Q1 2024 | 61,621 | $1.05M | <0.1% | +12,702+26.0% | Added | Holders |
| Q4 2023 | 48,919 | $498.5K | <0.1% | +9,217+23.2% | Added | Holders |
| Q3 2023 | 39,702 | $359.3K | <0.1% | −16,243−29.0% | Reduced | Holders |
| Q2 2023 | 55,945 | $602.0K | <0.1% | −17,627−24.0% | Reduced | Holders |
| Q1 2023 | 73,572 | $752.6K | <0.1% | −26,129−26.2% | Reduced | Holders |
| Q4 2022 | 99,701 | $1.05M | <0.1% | +22,261+28.7% | Added | Holders |
| Q3 2022 | 77,440 | $993.0K | <0.1% | −17,546−18.5% | Reduced | Holders |
| Q2 2022 | 94,986 | $1.22M | <0.1% | +94,986 | New | Holders |
| Q3 2021 | 0 | $0 | 0.0% | −60,319−100.0% | Sold out | Holders |
| Q2 2021 | 60,319 | $1.55M | <0.1% | −3,714−5.8% | Reduced | Holders |
| Q1 2021 | 64,033 | $2.67M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.